Prime time for doxorubicin-induced cardiotoxicity genetic testing

Tarek Magdy; Paul W. Burridge

doi:10.2217/pgs-2022-0032

Prime time for doxorubicin-induced cardiotoxicity genetic testing

Tarek Magdy, Paul W. Burridge^*

^*Corresponding author for this work

Pharmacology

Research output: Contribution to journal › Review article › peer-review

Original language	English (US)
Pages (from-to)	335-338
Number of pages	4
Journal	Pharmacogenomics
Volume	23
Issue number	6
DOIs	https://doi.org/10.2217/pgs-2022-0032
State	Published - Apr 2022

Funding

This work was supported by NIH NCI grant no. R01 CA220002 to PWB. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Keywords

cardiotoxicity
chemotherapy
clinical translation
human-induced pluripotent stem cells
pharmacogenomics

ASJC Scopus subject areas

Molecular Medicine
Genetics
Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/pgs-2022-0032

Cite this

@article{ba537f67b7c447c99b74f3f5ea4bb026,

title = "Prime time for doxorubicin-induced cardiotoxicity genetic testing",

keywords = "cardiotoxicity, chemotherapy, clinical translation, human-induced pluripotent stem cells, pharmacogenomics",

author = "Tarek Magdy and Burridge, {Paul W.}",

note = "Funding Information: This work was supported by NIH NCI grant no. R01 CA220002 to PWB. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.",

year = "2022",

month = apr,

doi = "10.2217/pgs-2022-0032",

language = "English (US)",

volume = "23",

pages = "335--338",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Future Medicine Ltd.",

number = "6",

}

TY - JOUR

T1 - Prime time for doxorubicin-induced cardiotoxicity genetic testing

AU - Magdy, Tarek

AU - Burridge, Paul W.

N1 - Funding Information: This work was supported by NIH NCI grant no. R01 CA220002 to PWB. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

PY - 2022/4

Y1 - 2022/4

KW - cardiotoxicity

KW - chemotherapy

KW - clinical translation

KW - human-induced pluripotent stem cells

KW - pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=85128350810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85128350810&partnerID=8YFLogxK

U2 - 10.2217/pgs-2022-0032

DO - 10.2217/pgs-2022-0032

M3 - Review article

C2 - 35380470

AN - SCOPUS:85128350810

SN - 1462-2416

VL - 23

SP - 335

EP - 338

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 6

ER -

Prime time for doxorubicin-induced cardiotoxicity genetic testing

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this